Autosomal Dominant Polycystic Kidney Disease Type 1 with Tuberous Sclerosis

Autosomal dominant polycystic kidney disease type 1 with tuberous sclerosis happens when a person is born with one large missing piece of DNA on chromosome 16 that cuts across two side-by-side genes: PKD1 (the main gene for ADPKD) and TSC2 (one of the two genes for tuberous sclerosis complex, TSC). Because both genes are affected at once, the person shows features of both diseases:

• Fast-growing kidney cysts starting in infancy or childhood, often more severe and earlier than usual ADPKD.

• Tuberous sclerosis features in brain, skin, heart, lungs, and kidneys (hamartomas and related signs).

Doctors call this a “contiguous gene deletion syndrome” because the same deletion touches two neighboring genes. Compared with typical ADPKD, kidney problems here usually start earlier and can progress faster in childhood or young adulthood. Because TSC is also present, people may have seizures, learning differences, skin marks, and heart or lung findings typical of TSC. Early recognition matters because surveillance and treatment plans from both the ADPKD and TSC guidelines are needed. PubMed+2revistanefrologia.com+2

TSC2-PKD1 contiguous gene syndrome happens when a person has one big missing piece of DNA that removes parts of two side-by-side genes: TSC2 (causes tuberous sclerosis complex, or TSC) and PKD1 (causes autosomal dominant polycystic kidney disease, or ADPKD). Because both genes are affected, people can have signs of TSC (skin spots, seizures, brain and kidney tumors called angiomyolipomas) and also many kidney cysts from ADPKD—often earlier and more severe than usual. This combined picture explains the longer name “autosomal dominant polycystic kidney disease type 1 with tuberous sclerosis.” NCBI+2jmg.bmj.com+2

This combined condition raises the risk of fast kidney growth, early loss of kidney function, and bleeding from kidney angiomyolipomas. It also brings the usual TSC concerns (such as seizures and brain growths like SEGA) and the usual ADPKD issues (such as high blood pressure and pain from cysts). Because these problems can add up, people need regular imaging, blood-pressure control, kidney-protective habits, and sometimes specialized medicines or procedures. TSC Alliance+2TSC Alliance+2

Other names

• TSC2/PKD1 contiguous gene deletion syndrome

• TSC2–PKD1 contiguous gene syndrome

• PKDTS (short for “polycystic kidney disease–tuberous sclerosis”)

• OMIM #600273 (catalog entry)
  All of these mean the same combined condition caused by a single deletion spanning TSC2 and PKD1. jmg.bmj.com+1

---

Types

Because this syndrome is rare, doctors “type” it using practical clinical patterns rather than rigid bins:

1. By kidney severity and timing

• Infant-onset / early childhood-onset severe cystic disease with big kidneys and many cysts early in life. This is the classic picture. jmg.bmj.com+1

• Childhood-to-adolescent onset with variable speed, which newer reports show can happen. PubMed

2. By size and content of the deletion

• Large deletions removing many exons (sections) of TSC2 and PKD1 often give the most severe kidney course.

• Smaller or mosaic deletions may cause milder or more mixed findings. (Genetic labs define the exact breakpoints.) Nature

3. By organ involvement beyond kidneys

• TSC-predominant: seizures, cortical tubers, subependymal nodules, cardiac rhabdomyomas, skin signs.

• Renal-predominant: kidneys drive symptoms and risk.
  Most people have a mix, so care teams follow both TSC and ADPKD surveillance pathways. NCBI+1

4. By age group

• Infant/young child (rhabdomyomas, early cysts).

• Older child/teen (seizures, learning issues, progressive kidney enlargement).

• Young adult (decline in kidney function, liver cysts, aneurysm screening). NCBI+1

---

Causes

Note: “Causes” here means biologic reasons and modifiers that lead to the combined disease picture or make it worse/faster. The root cause is always a germline deletion spanning TSC2 and PKD1.

1. Single large deletion across TSC2 and PKD1 removes both genes at once, creating the dual disease. jmg.bmj.com

2. Loss of tuberin (from TSC2) drives overactive mTOR signaling, which promotes hamartomas and can worsen kidney cyst growth. PubMed

3. Loss of polycystin-1 (from PKD1) disrupts tubular sensing and fluid signaling, causing cyst formation and enlargement. PubMed

4. Second-hit somatic mutations in kidney cells (common in tumor/cyst biology) accelerate local cyst growth. Nature

5. Larger deletion size taking out more of each gene often correlates with earlier, more severe kidneys. Nature

6. Mosaicism (deletion in some cells but not others) can soften or vary the picture. Nature

7. Genetic background/modifiers elsewhere in the genome may change speed of kidney decline. (Shown in ADPKD generally.) PubMed

8. Poorly controlled high blood pressure speeds kidney damage in cystic disease. PubMed

9. High total kidney volume (TKV) indicates aggressive disease and predicts faster function loss. PubMed

10. Recurrent kidney infections or stones can aggravate scarring and function decline. PubMed

11. Female-predominant liver cyst growth (common in ADPKD) can burden health and nutrition, indirectly stressing kidneys. Lippincott Journals

12. Intracranial aneurysms (ADPKD risk) can occur and add neurologic risk in a person who also has TSC brain lesions. NCBI

13. Seizures (TSC) raise injury risk and hospitalizations, complicating overall disease control. PubMed

14. Cardiac rhabdomyomas in infancy can cause arrhythmias or outflow problems, raising care complexity. PubMed

15. Lymphangioleiomyomatosis (LAM) in females adds lung cysts and pneumothorax risk. PubMed

16. Chronic pain from cysts or angiomyolipomas can reduce activity and sleep, worsening quality of life. PubMed

17. Hematuria episodes (cyst bleeding) can cause anemia or need for procedures. PubMed

18. Pregnancy in people with severe polycystic kidneys can unmask or worsen hypertension and complications. PubMed

19. Medication choices (e.g., chronic NSAIDs) may strain kidneys if overused. Clinical guidance stresses kidney-safe plans. PubMed

20. Delayed diagnosis means missed surveillance and late treatment, allowing faster, unchecked progression. Early genetic testing helps. Nature

---

Symptoms

1. Big belly from enlarged kidneys—kidneys grow with many cysts; abdomen may look or feel full. jmg.bmj.com

2. Flank or back pain—stretching of the kidney capsule or cyst bleeding can hurt. PubMed

3. Blood in the urine—from cyst rupture or stones. PubMed

4. Frequent urination or nighttime urination—impaired concentrating ability early in cystic disease. PubMed

5. High blood pressure—very common in ADPKD; often appears in childhood in this syndrome. PubMed

6. Kidney infections or fever—infected cysts can cause pain and high temperature. PubMed

7. Poor growth or feeding in infants—if kidneys are very large or if there are heart issues from TSC. PubMed

8. Seizures—the most common neurologic feature of TSC; may begin in infancy. PubMed

9. Developmental delays or learning differences—part of the TSC spectrum. PubMed

10. Skin changes—light patches (hypomelanotic macules), facial angiofibromas, shagreen patches, or nail fibromas. TSC Alliance

11. Heart rhythm problems—from infant cardiac rhabdomyomas in TSC. PubMed

12. Shortness of breath or collapsed lung—women with LAM (a TSC-related lung disease) can have pneumothorax. PubMed

13. Headaches or visual changes—rarely from brain growths or aneurysms that need imaging. NCBI

14. Abdominal fullness after meals—from very large liver cysts (ADPKD extra-renal feature). Lippincott Journals

15. Fatigue—common in chronic kidney disease as function drops. PubMed

---

Diagnostic tests

A) Physical-exam–based tests (simple, bedside)

1. Blood pressure measurement—key in every visit; high readings are common and harmful to kidneys. PubMed

2. Abdominal exam and tape measurement—feels enlarged kidneys; serial measures track change. PubMed

3. Detailed skin exam in good light—looks for TSC skin signs: hypomelanotic macules, angiofibromas, shagreen, ungual fibromas. TSC Alliance

4. Neurologic exam—assesses tone, reflexes, development, and seizure sequelae. PubMed

5. Growth and developmental checks in children—plot height/weight/head size; look for delays needing therapy. PubMed

B) “Manual” office tests (simple tools; low tech)

6. Wood’s-lamp skin exam—makes faint light patches easier to see in TSC. TSC Alliance

7. Funduscopic (eye) exam—looks for retinal hamartomas or achromic patches. TSC Alliance

8. Urine dipstick in clinic—screens for blood or protein quickly. PubMed

9. Pain/provocation maneuvers for CVA tenderness—helps suggest infected or bleeding cysts. PubMed

10. Orthostatic vitals—checks dehydration or autonomic impact if symptoms suggest. PubMed

C) Laboratory & pathological tests

11. Serum creatinine with eGFR—core kidney function index; track over time. PubMed

12. Urinalysis and urine albumin-to-creatinine ratio—detect hematuria and albuminuria. PubMed

13. Electrolytes, bicarbonate, hemoglobin, iron studies—stage CKD complications (acidosis, anemia). PubMed

14. Genetic testing for a TSC2/PKD1 deletion—methods like targeted panels + MLPA/quantitative PCR or chromosomal microarray confirm the contiguous deletion. Nature

15. Pathology when needed (rare)—analysis of resected angiomyolipoma or atypical lesions to confirm hamartoma and rule out malignancy. PubMed

D) Electro-diagnostic tests

16. EEG—evaluates seizures common in TSC; guides anti-seizure therapy. PubMed

17. ECG—screens for rhythm issues from cardiac rhabdomyomas or electrolytes. PubMed

18. Holter monitoring (ambulatory ECG)—captures intermittent arrhythmias if symptoms occur. PubMed

E) Imaging tests

19. Kidney ultrasound (first-line in children) and MRI (for detailed cyst mapping and Total Kidney Volume, TKV)—MRI TKV helps predict risk and plan therapy. PubMed

20. Brain MRI (TSC surveillance) to assess cortical tubers, subependymal nodules, and subependymal giant cell astrocytoma (SEGA); MRA if aneurysm risk is present. Add chest HRCT in at-risk females to assess LAM; abdominal MRI/CT for liver cysts and angiomyolipomas. PubMed+2NCBI+2

Non-pharmacological treatments (therapies & others)

1. Kidney-protective blood-pressure plan
   Description. Keeping blood pressure in the healthy range lowers stress on kidney blood vessels and slows kidney damage over time. In clinic, the team chooses a personal target (often <120–130 systolic for many people with CKD) and checks pressure at home. Sodium is limited (see item 3), medicines are adjusted (see drug section), and sleep, weight, and activity are tuned to help. Purpose. Protect kidney function and lower the chance of heart and brain complications. Mechanism. Less pressure inside cyst-rich kidneys reduces stretch and scarring; better vessel health also prevents kidney and brain vessel problems. KDIGO+1

2. Structured water intake
   Description. Drinking enough plain water through the day helps prevent dehydration, kidney stones, and sometimes reduces pain from cyst bleeding or clots. The amount should be individualized by your clinician, especially if you are on tolvaptan or have heart issues. Purpose. Support kidney filtration, prevent stone formation, and protect overall kidney health. Mechanism. Adequate hydration dilutes urine, lowers stone-forming salts, and helps flush the urinary tract. (Your team will tailor volume to avoid sodium loss or low sodium in blood.) NIDDK+1

3. Lower-sodium, kidney-wise nutrition
   Description. A diet with less salt (for many, ~2 grams sodium/day) helps control blood pressure and reduces fluid retention. Protein is moderate (not high), ultra-processed foods are limited, and potassium/phosphorus are adjusted if kidney function drops. A renal dietitian makes a practical plan that fits culture, budget, and taste. Purpose. Support blood-pressure targets and slow chronic kidney disease (CKD) progression. Mechanism. Less sodium lowers vascular resistance and fluid overload; balanced macronutrients reduce kidney workload. NIDDK+1

4. Avoidance of kidney toxins (NSAIDs and contrast when possible)
   Description. Many over-the-counter pain pills (like ibuprofen, naproxen) can strain kidneys. Iodinated contrast for CT scans can also hurt vulnerable kidneys. Your team uses acetaminophen first for pain and prefers MRI or ultrasound for follow-up when appropriate. Purpose. Prevent sudden kidney injury and long-term decline. Mechanism. Avoiding prostaglandin-blocking drugs and nephrotoxic exposures protects blood flow and tubular cells in cyst-heavy kidneys. KDIGO+1

5. Regular kidney imaging and labs
   Description. People with TSC and ADPKD need periodic kidney imaging (often MRI or ultrasound) and blood/urine tests to catch growth of cysts or angiomyolipomas, check filtration (eGFR), and watch for bleeding or infection. Purpose. Early detection so treatment can start before complications occur. Mechanism. Imaging shows structure; labs show function and inflammation. Schedules are individualized (for TSC kidneys, MRI every 1–3 years is a common expert recommendation). TSC Alliance+1

6. Home blood-pressure monitoring
   Description. Measuring at home (morning and evening) shows true daily control and guides safe medicine changes. Purpose. Reach targets faster and maintain them safely. Mechanism. Frequent readings reveal patterns (like morning surges) that clinic checks can miss, allowing precise therapy. KDIGO

7. UTI prevention habits
   Description. Hydration, timely urination, gentle hygiene, and early reporting of fever, flank pain, or burning can limit urinary infections, which are more complex when cysts are present. Purpose. Avoid kidney infections and sepsis; prevent infected cysts. Mechanism. Lower bacterial load and faster care reduce spread into cysts. NIDDK

8. Activity with cyst-safe precautions
   Description. Regular exercise helps weight, blood pressure, sleep, and mood. Heavy contact or high-impact activities may raise the chance of cyst or AML bleeding. Your team will guide sports choices and protective steps. Purpose. Gain heart-kidney benefits while avoiding bleeds. Mechanism. Fitness improves vascular health; avoiding abdominal trauma lowers rupture risk in enlarged kidneys or AML. TSC Alliance

9. Weight management and metabolic health
   Description. Healthy weight, balanced meals, and regular activity support blood pressure and lower inflammation. Diabetes risk is addressed with diet, movement, and medicines if needed. Purpose. Slow kidney scarring and protect heart and brain. Mechanism. Less insulin resistance and less adipose-driven inflammation reduce CKD progression risks. KDIGO

10. Sleep apnea screening and treatment
    Description. Snoring, pauses in breathing, and daytime sleepiness can signal sleep apnea, which worsens blood pressure and kidney decline. Testing and CPAP can help. Purpose. Improve blood pressure, daytime energy, and kidney outcomes. Mechanism. Treating nocturnal hypoxia reduces sympathetic drive and vascular injury. KDIGO

11. Pain management pathway (non-opioid first)
    Description. Start with heat, gentle stretching, topical agents, and acetaminophen; add nerve-targeted therapies or procedures if pain persists. Avoid routine NSAIDs. Purpose. Control pain without harming kidneys. Mechanism. Multimodal pain care lowers drug toxicity while addressing muscle, nerve, or cyst causes. KDIGO

12. Genetic counseling and family planning
    Description. A counselor explains inheritance (autosomal dominant), testing options, pregnancy issues, and reproductive choices. Purpose. Support informed decisions and early care for relatives at risk. Mechanism. Understanding risk allows timely screening and management. NCBI

13. Seizure-safety education (for the TSC side)
    Description. If seizures occur, families learn rescue steps, triggers, and when to call for help; schools and workplaces get simple action plans. Purpose. Lower injury risk and time to treatment. Mechanism. Prepared responses shorten seizure duration and complications. NCBI

14. MRI-based AML surveillance with bleed-risk planning
    Description. For kidney angiomyolipomas, teams track size and growth and plan ahead for mTOR therapy or selective embolization if lesions are large or growing. Emergency plans are discussed for sudden flank pain. Purpose. Prevent life-threatening bleeding. Mechanism. Imaging flags high-risk AMLs; early therapy shrinks them and stabilizes vessels. TSC Alliance+1

15. Brain and skin TSC surveillance (coordinated care)
    Description. Because TSC affects many organs, coordinated dermatology, neurology, nephrology, and ophthalmology care finds and treats problems early. Purpose. Whole-person safety and quality of life. Mechanism. Regular checks catch SEGA, retinal changes, or skin lesions before complications. NCBI

16. Aneurysm risk discussion (ADPKD side)
    Description. Some people with ADPKD have a higher risk of brain aneurysm, especially with family history or prior bleed. Doctors discuss screening MRI in selected cases. Purpose. Prevent hemorrhagic stroke. Mechanism. Targeted screening identifies aneurysms for monitoring or repair. KDIGO

17. Vaccinations and infection prevention
    Description. Staying current with vaccines (flu, COVID-19, pneumococcal, hepatitis as advised) reduces infections that can shock kidneys. Dental care and skin care also matter. Purpose. Protect kidney function and overall health. Mechanism. Fewer severe infections means fewer acute kidney hits and fewer hospital stays. KDIGO

18. Mental health and peer support
    Description. Chronic disease brings stress. Counseling, mindfulness, and patient groups help coping, adherence, and family communication. Purpose. Improve daily functioning and decision-making. Mechanism. Lower stress hormones and better routines support blood pressure and kidney health. KDIGO

19. Medication review for interactions
    Description. Because everolimus and tolvaptan use CYP3A pathways and carry liver risks, pharmacists and clinicians check every new drug and supplement. Purpose. Prevent side effects and keep levels safe. Mechanism. Avoiding CYP3A inhibitors/inducers and hepatotoxins prevents toxicity or loss of effect. KDIGO+1

20. Early referral to transplant team (when kidney failure approaches)
    Description. Meeting the transplant team early helps planning, live donor discussions, and dialysis choices if needed. Purpose. Smooth, timely transition and better outcomes. Mechanism. Early evaluation reduces wait times and complications. KDIGO

---

Drug treatments

⚠️ Important: Doses below are typical adult label doses; your clinician will individualize based on kidney function, liver tests, age, interactions, and pregnancy/lactation. Always follow your own prescriber’s instructions.

1. Tolvaptan (Jynarque®) – V2-receptor antagonist
   Dose/Time. Split daily dosing: start 45 mg on waking + 15 mg ~8 h later; if tolerated, titrate to 60/30 then 90/30 mg/day; strict REMS liver-test schedule (monthly for 18 months, then every 3 months). Purpose. Slow kidney function decline in adults at risk of rapidly progressing ADPKD. Mechanism. Blocks vasopressin V2 receptors, lowering kidney cAMP signaling that drives cyst growth and fluid secretion. Side effects. Thirst, frequent urination, dry mouth, hypernatremia; rare but serious liver injury (hence REMS/lab monitoring); avoid strong CYP3A inhibitors. FDA Access Data+1

2. Everolimus (Afinitor® / Afinitor Disperz®) – mTOR inhibitor
   Dose/Time. For TSC renal angiomyolipoma not requiring immediate surgery, a common adult dose is 10 mg once daily (swallow whole); TSC-associated SEGA or seizures use weight/level-guided dosing (Disperz for suspension). Purpose. Shrinks angiomyolipomas, controls SEGA, and reduces TSC-associated partial-onset seizures. Mechanism. Inhibits mTOR, the overactive growth pathway in TSC, slowing abnormal cell growth and reducing tumor volume. Side effects. Mouth sores, infections, high lipids/glucose, pneumonitis, edema; CYP3A interactions. FDA Access Data+1

3. Cannabidiol (Epidiolex®) – anti-seizure
   Dose/Time. Start 2.5 mg/kg twice daily (5 mg/kg/day); may increase to 10–20 mg/kg/day based on response/tolerability; check liver tests if on valproate. Purpose. Reduce seizures associated with TSC (also LGS, Dravet) in patients ≥1 year. Mechanism. Modulates neuronal excitability via multiple targets (including GPR55, TRP channels). Side effects. Sleepiness, diarrhea, decreased appetite, transaminase elevations (esp. with valproate), interactions with clobazam and CYP enzymes. FDA Access Data

4. Vigabatrin (Sabril®) – GABA transaminase inhibitor
   Dose/Time. Titrated per label; used for infantile spasms and refractory focal seizures (including in TSC) in specific settings; ophthalmic monitoring required due to vision risk. Purpose. Control seizures, especially infantile spasms in TSC infants. Mechanism. Irreversibly inhibits GABA-T, increasing brain GABA. Side effects. Permanent vision loss risk (REMS), drowsiness, weight gain; adjust in renal impairment. FDA Access Data

5. ACE inhibitor (Lisinopril) – RAAS blocker
   Dose/Time. Typical start 10 mg daily, titrate; adjust for kidney function and potassium. Purpose. Treat hypertension and reduce proteinuria in CKD/ADPKD. Mechanism. Lowers angiotensin II and aldosterone, relaxing vessels and reducing intraglomerular pressure. Side effects. Cough, hyperkalemia, kidney function changes, angioedema (rare). FDA Access Data

6. ARB (Losartan) – RAAS blocker
   Dose/Time. Often 50–100 mg daily. Purpose. Hypertension and kidney protection when ACEI not tolerated. Mechanism. Blocks AT1 receptors to reduce vasoconstriction and aldosterone; kidney-protective in proteinuric states. Side effects. Dizziness, hyperkalemia, renal function changes; avoid in pregnancy. FDA Access Data

7. Thiazide diuretic (Hydrochlorothiazide) – diuretic/antihypertensive
   Dose/Time. 12.5–25 mg in the morning. Purpose. Add-on for blood-pressure control and kidney stone prevention in hypercalciuria. Mechanism. Promotes sodium/water excretion and lowers calcium excretion in urine. Side effects. Low sodium/potassium, dizziness, photosensitivity, gout flares. FDA Access Data

8. Calcium-channel blocker (Amlodipine) – vasodilator
   Dose/Time. 5–10 mg daily. Purpose. Additional blood-pressure control if needed. Mechanism. Blocks L-type calcium channels in vascular smooth muscle to relax arteries. Side effects. Leg swelling, flushing, headache, gingival overgrowth. FDA Access Data

9. Beta-blocker (Labetalol) – alpha/beta blocker
   Dose/Time. 100–400 mg twice daily. Purpose. BP control, especially in pregnancy-planning or episodes of high sympathetic tone. Mechanism. Reduces heart rate and vascular resistance. Side effects. Fatigue, dizziness; caution with asthma. FDA Access Data

10. Loop diuretic (Furosemide) – diuretic for edema
    Dose/Time. Individualized; often morning dosing. Purpose. Manage fluid overload in advanced CKD. Mechanism. Blocks NKCC2 in the loop of Henle to increase salt and water excretion. Side effects. Low potassium/magnesium, dehydration, ototoxicity at high dose. FDA Access Data

11. Atorvastatin (Lipitor®) – statin
    Dose/Time. 10–80 mg nightly. Purpose. Treat high LDL and reduce cardiovascular risk, which is important in CKD/ADPKD. Mechanism. Inhibits HMG-CoA reductase to lower cholesterol and plaque risk. Side effects. Muscle aches, rare rhabdomyolysis, liver enzyme elevations. FDA Access Data

12. Potassium citrate (urine alkalinizer) – stone prevention
    Dose/Time. Divided doses with meals; titrate to urine citrate/pH goals. Purpose. Prevent uric-acid and calcium stones, which can worsen kidney pain and infections. Mechanism. Raises urinary citrate (binds calcium) and pH (dissolves uric acid). Side effects. GI upset; avoid if hyperkalemia risk. FDA Access Data

13. Nitrofurantoin (Macrobid®) – antibiotic for lower UTI
    Dose/Time. 100 mg twice daily for short courses; avoid if eGFR is low per label. Purpose. Treat bladder infections promptly to avoid ascent into cysts. Mechanism. Bacterial enzyme inhibition and DNA damage in urinary pathogens. Side effects. Nausea, rare lung/liver toxicity; not for pyelonephritis. FDA Access Data

14. Trimethoprim-sulfamethoxazole (Bactrim®) – antibiotic
    Dose/Time. Standard dosing for UTI; adjust for kidney function. Purpose. Treat or suppress recurrent UTIs in selected patients. Mechanism. Blocks folate pathways (sequential inhibition). Side effects. Rash, hyperkalemia, kidney effects; interactions with RAAS blockers. FDA Access Data

15. Ciprofloxacin – fluoroquinolone antibiotic
    Dose/Time. Label-guided dosing; adjust in CKD. Purpose. Treat complicated UTIs or infected cysts (good penetration). Mechanism. Inhibits bacterial DNA gyrase/topoisomerase. Side effects. Tendon rupture risk, QT prolongation, CNS effects. Use carefully. FDA Access Data

16. Acetaminophen (Paracetamol) – analgesic/antipyretic
    Dose/Time. Up to 3,000 mg/day in most adults (watch combination products). Purpose. First-line pain/fever relief without harming kidneys. Mechanism. Central COX inhibition (non-anti-inflammatory). Side effects. Liver toxicity if overdosed or with heavy alcohol use. FDA Access Data

17. Topical lidocaine – local anesthetic for focal pain
    Dose/Time. Patches up to 12 h on/12 h off. Purpose. Reduce localized neuropathic or myofascial pain without systemic effects. Mechanism. Sodium-channel blockade in peripheral nerves. Side effects. Local skin irritation. FDA Access Data

18. Gabapentin – neuromodulator for neuropathic pain
    Dose/Time. Titrated; adjust in CKD. Purpose. Manage chronic flank or neuropathic components when present. Mechanism. Binds α2δ subunit of calcium channels, reducing excitatory neurotransmission. Side effects. Sedation, dizziness. FDA Access Data

19. Everolimus (re-listed for seizures – Disperz) – mTOR inhibitor for TSC seizures
    Dose/Time. Weight/therapeutic-level guided; used with neurology monitoring. Purpose. Reduce frequency of TSC-associated partial-onset seizures. Mechanism. Same mTOR pathway down-regulation; helps stabilize abnormal cortical networks. Side effects. As above (stomatitis, infection risk, lipids/glucose). FDA Access Data

20. Cannabidiol (re-listed for completeness in TSC seizures) – anti-seizure
    Dose/Time. 10–20 mg/kg/day in two doses after titration. Purpose. Adjunct to reduce seizure burden in TSC. Mechanism. Modulates neuronal excitability through multiple non-CB1 pathways. Side effects. Sleepiness, GI upset, LFT changes; check interactions. FDA Access Data

---

Immunity booster / regenerative / stem-cell drugs

The FDA has not approved any stem-cell or “immunity-booster” drugs for treating ADPKD, TSC, or this combined syndrome. The FDA regularly warns patients to avoid unapproved stem-cell products offered outside clinical trials. If you’re considering such therapies, talk with your specialist and check FDA resources. U.S. Food and Drug Administration

---

Dietary molecular supplements

⚠️ Supplements can interact with prescription drugs (especially everolimus and tolvaptan) and may need dose changes in CKD. Discuss each item with your clinician.

1. Omega-3 (fish oil, EPA/DHA)
   Dose. Often 1–2 g/day of combined EPA/DHA. Function. Heart-protective in CKD, may reduce triglycerides and systemic inflammation. Mechanism. Resolvin/protectin pathways and membrane effects decrease inflammatory signaling that can worsen vascular disease in CKD. KDIGO

2. Vitamin D (cholecalciferol, or per plan in CKD)
   Dose. Personalized to labs; often 1,000–2,000 IU/day or as prescribed. Function. Bone and immune health; helps manage CKD-mineral-bone disorder as guided by labs. Mechanism. Activates vitamin-D receptors to improve calcium/phosphate balance and modulate immunity. KDIGO

3. Vitamin B-complex (esp. B12/folate if low)
   Dose. Daily multivitamin or targeted doses per labs. Function. Support energy pathways and red-blood-cell production; some CKD diets are low in B vitamins. Mechanism. Cofactors in DNA synthesis and mitochondrial metabolism. KDIGO

4. Magnesium (if low and if no contraindication)
   Dose. 200–400 mg/day, adjusted for kidney function. Function. Prevents constipation from medications and may reduce stone risk. Mechanism. Competes with calcium crystallization and supports vascular tone. KDIGO

5. Probiotics (general gut support)
   Dose. Per product (≥10^9 CFU/day common). Function. May reduce uremic toxins and help bowel regularity on restricted diets. Mechanism. Modifies gut microbiome metabolism of nitrogenous waste. KDIGO

6. Coenzyme Q10
   Dose. 100–200 mg/day. Function. Antioxidant support for fatigue; evidence mixed in CKD. Mechanism. Electron transport cofactor and free-radical scavenger. KDIGO

7. Citrate (as lemon/lime juice if tablets not used)
   Dose. Food-based citrate daily. Function. Stone prevention support. Mechanism. Raises urinary citrate and pH, limiting crystal formation. KDIGO

8. Plant-forward fiber (psyllium, inulin)
   Dose. 5–10 g/day added fiber, adjust for tolerance. Function. Improves bowel regularity, supports heart-kidney health, may lower uremic toxins via microbiome. Mechanism. Fermentable fiber produces short-chain fatty acids with anti-inflammatory effects. KDIGO

9. Turmeric/curcumin (with caution for interactions)
   Dose. 500–1,000 mg/day standardized extract; review with pharmacist due to CYP interactions. Function. Anti-inflammatory symptom support. Mechanism. NF-κB pathway modulation and antioxidant effects. KDIGO

10. Protein optimization (whey/renal-friendly blends as needed)
    Dose. Per dietitian plan (often ~0.8 g/kg/day in CKD unless otherwise directed). Function. Preserve muscle without overloading kidneys. Mechanism. Balanced essential amino acids without excess nitrogen load. NIDDK

---

Surgeries/procedures

1. Selective renal artery embolization (for AML bleed or high-risk size)
   Procedure. A catheter delivers tiny particles or coils to block blood flow to an angiomyolipoma. Why. First-line for acute AML hemorrhage; also used to reduce bleeding risk in large/growing AMLs. TSC Alliance

2. Kidney-sparing AML resection (partial nephrectomy) – select cases
   Procedure. Surgeon removes the AML while preserving as much kidney as possible. Why. Alternative when embolization is not suitable or fails. Nephrectomy should be avoided if kidney-sparing options exist. TSC Alliance

3. Laparoscopic cyst fenestration/decortication (pain from dominant cysts)
   Procedure. Surgeon opens or removes the wall of large surface cysts to decompress them. Why. Reduce persistent pain or mass effect when other measures fail. KDIGO

4. SEGA resection (brain) – selected TSC patients
   Procedure. Neurosurgeon removes a growing subependymal giant cell astrocytoma if medication is not enough or hydrocephalus threatens. Why. Prevent blockage of CSF flow and neurological damage. FDA Access Data

5. Kidney transplantation (for kidney failure)
   Procedure. Surgical placement of a donor kidney; lifelong anti-rejection medicines are needed. Why. Best long-term replacement for lost kidney function in ADPKD/TSC2-PKD1 once dialysis or pre-emptive transplant is indicated. KDIGO

---

Preventions

1. Control blood pressure at target with home checks and clinic follow-up. KDIGO

2. Limit sodium; work with a renal dietitian on a kidney-wise meal plan. NIDDK

3. Stay well hydrated (personalized plan, especially if on tolvaptan). FDA Access Data

4. Avoid routine NSAIDs; ask before any new medicine or supplement. KDIGO

5. Keep imaging and lab appointments on schedule to catch issues early. TSC Alliance

6. Follow mTOR/REMS monitoring exactly if on everolimus or tolvaptan. FDA Access Data+1

7. Prevent and treat UTIs quickly; know your symptom plan. NIDDK

8. Exercise regularly with cyst-safe precautions; avoid abdominal trauma. TSC Alliance

9. Stay up-to-date with vaccines to reduce severe infections. KDIGO

10. Engage mental-health and peer support to sustain long-term habits. KDIGO

---

When to see a doctor (red flags)

Contact your care team urgently for sudden severe flank or abdominal pain, blood in urine, fever/chills, fainting or severe headache, rapid belly growth, yellow eyes/skin (possible liver injury if on tolvaptan/everolimus), or worsening swelling, breathlessness, or confusion. Early evaluation can prevent severe bleeding, infected cysts, aneurysm complications, or drug-related liver problems. Keep routine visits for blood pressure, labs, and imaging. FDA Access Data+1

---

What to eat and what to avoid

What to eat. Choose fresh, minimally processed foods, plenty of vegetables and fruits (as allowed for potassium level), whole grains, lean proteins in moderate amounts, plant oils, and adequate water spaced through the day. Work with a renal dietitian to adjust protein, potassium, and phosphorus as kidney function changes. NIDDK

What to avoid or limit. Limit salt, ultra-processed foods, excess added sugars, very high-protein fad diets, excess caffeine if your team advises, and alcohol binges. Avoid routine NSAIDs and unreviewed supplements that can interact with your medicines. NIDDK+1

---

Frequently asked questions (FAQs)

1. Is this syndrome rare?
   Yes. It results from a single large deletion affecting TSC2 and PKD1. It is rarer than having either TSC or ADPKD alone. jmg.bmj.com

2. How is it different from “regular” ADPKD?
   Kidney cysts often appear earlier and grow faster, and kidney angiomyolipomas are more common because of the TSC side. jmg.bmj.com+1

3. What is the main medicine proven to slow ADPKD kidneys?
   Tolvaptan (Jynarque) for adults at risk of rapid progression, under REMS liver monitoring. FDA Access Data

4. What medicine shrinks TSC-related kidney angiomyolipomas?
   Everolimus (an mTOR inhibitor) is FDA-approved for this and for TSC-related SEGA and seizures. FDA Access Data

5. What helps TSC-related seizures?
   Cannabidiol (Epidiolex) and everolimus are FDA-approved options; plans are individualized. FDA Access Data+1

6. Should everyone with ADPKD take tolvaptan?
   No. It’s for adults at risk of rapid progression after careful evaluation and discussion of benefits, liver-test monitoring, and side effects. KDIGO

7. Are there approved stem-cell or “immune-booster” cures?
   No. FDA warns against unapproved stem-cell products; use clinical trials or approved therapies only. U.S. Food and Drug Administration

8. What blood-pressure target should I aim for?
   Your team personalizes it; many CKD patients benefit from lower systolic targets with home monitoring. KDIGO

9. Can caffeine speed cyst growth?
   Data are mixed; moderating intake is reasonable—follow your team’s advice. KDIGO

10. Do I need brain vessel screening?
    Selected people with family history or prior aneurysm may be screened. Ask your clinician. KDIGO

11. How often should my kidneys be imaged?
    Your schedule is individualized; many TSC experts advise MRI every 1–3 years for kidneys. TSC Alliance

12. Can pregnancy be safe?
    Yes, with planning. Blood-pressure control and specialist care lower risks; some drugs are unsafe in pregnancy. KDIGO

13. When is embolization used?
    For AML bleeding or high-risk size/growth to prevent rupture. TSC Alliance

14. If my kidneys fail, what next?
    Dialysis or, preferably, kidney transplant when appropriate. Early referral helps. KDIGO

15. Where can I find trusted guidelines?
    See KDIGO 2025 ADPKD guideline and TSC Alliance surveillance/treatment guidance; your care team will tailor these to you. KDIGO+2KDIGO+2

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 04, 2025.